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INTRODUCTION 
Stroke is the third leading cause of mortality in developed 
countries after coronary heart disease and cancer.
1
 It was 
estimated that the incidence of stroke is predicted to 
increase over the next 5-10 years by 12% in the general 
population and by 20% in low-income subjects.
2
 
Mortality rates during the first 30 days after stroke and at 
1 year are 20% and 30%, respectively. The large majority 
(65-85%) of strokes in the Western world are ischemic 
whereas haemorrhagic strokes, which are less frequent, 
are more disabling.
3
  
Stroke remain as a common issue in the health system 
and is one of three causes of death in many countries and 
a large part of neurological damage associated with 
stroke, which would impose enormous costs to the health 
system.
4
 
Stroke is a syndrome of acute neurologic symptoms for at 
least 24 hours to be determined. Acute onset and duration 
of symptoms is determined based on the patient's history 
and a neurological examination which confirmed by CT-
Scan and MRI.
5
 
Stroke causes to symptoms and type of them related to 
one area of brain which feeding by vessels. In cerebral 
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ischemia, the occlusion cause to cut off blood flow in a 
specified area of the brain and disorder due to the 
neurological actions in this area cause to incidence of 
similar symptoms.
6
 
Cut off blood flow, deal to exclusion of neurons and 
other cells from glucose and oxygen and in the non-rapid 
establishment of blood flow deal to cell death and type of 
it related to ischemic severity. Many factors such as 
HTN, more Alcohol consumption, uses contraceptive 
drugs and genetic have main role in incidence of stroke. 
Stroke is also the result of numerous mendelian disorder 
that mainly affects the heart and blood vessels, such as 
cardiomyopathy and arrhythmias family, homocystinuria, 
dyslipidemia, hemoglobinopathy, coagulopathy and 
connective tissue disorders and migraines. In addition, 
there is a variety of monogenic syndrome, in which the 
main manifestation is stroke but the causes of more 
strokes probably multi-factorial included environmental 
and multi-genetic factors.
5
 
Early diagnosis and true management of stroke is 
important in prognosis of patients. 
Many efforts have been done about the decreasing of 
mortality in patients with ischemic stroke which one of 
them is the effect of neuroprotective agents in stroked 
patients.
3
 
Neuroprotective drugs had been prescribed some hour 
after ischemia and could be decrease the volume of 
infarcts.
7 
 
Based on recent studies it seem that albumin cause to 
recovery rate in prognosis of patients with ischemia. 
Tabernero and et al in a study showed that in pathological 
condition, albumin enter brain cells and may help 
maintain neuronal metabolism by increasing 
mechanisms.
8
  
Belayev and et al in a study showed that treatment with 
moderate dose of albumin cause to recovery in neurologic 
condition, decreasing infarct volume and brain edema.
9
 
Albumin is a protein soluble in water and one of the most 
important proteins in the plasma, which accounts for 65-
55% of total protein in the body. Albumin is made in the 
liver and decrease in the liver, kidney, malnutrition and 
diabetes. The main function of albumin is tuning blood 
colloid osmotic pressure and its amount related to 
production, destruction, nutrition, blood oncotic pressure, 
liver disease, kidney disease and other chronic diseases. 
The use of albumin is considered as an independent risk 
factor for mortality in the elderly. There wasn’t similar 
study in Iran on the role of albumin in stroke and because 
of the ischemic stroke is the most common mortality 
causes and its side effects deal to burden disease in 
society, so doing study on drugs and methods which can 
improve the prognosis of stroke and less disability of 
disease is important. The aim of this study was to 
investigate the albumin impact on clinical practice and 
complications of ischemic stroke in patients with stroke. 
METHODS 
This is a randomized clinical trial study that has been 
done on 100 stroked patients referred to Alavi hospital in 
Ardabil. Patients randomly divided in two groups each 
with 50 patients. One group receive albumin 20% with 
doses 2 gr/kg body weight for one week and other group 
take normal saline similar to first group. Two groups 
followed by three months. The inclusion criteria were 
age>18, low time of start clinical signs (<12 hour) and 
exclusion criteria were patients have kidney disease with 
creatinine more than 2.5, pregnant patients, haemorrhagic 
stroke, SBP>220 Mm Hg and DBP<90 Mm Hg, distress, 
heart block, advanced systemic disease, brain tumor, 
abscess and. 
NIHSS questionnaire completed for each patient based on 
their interview and medical documents in hospital 
according the specialist doctor ideas. In NIHSS 
questionnaire the level of consciousness were, staring at 
the lesion ability to move in the opposite hemisphere, the 
field of vision, facial paresis, arm movement assessment 
(the paralysis), leg movements (the paralysis), sensory 
impairment assessments, ability to speak, ataxia and 
Extinction and neglect (excitation of each half on one 
side of the body just found stimulation) was assessed 
based on the severity of the stroke and the score from 0 to 
42 detected for each item. In patients without symptoms 
of stroke the zero score and to patients with severe stroke 
score 21-42 score was rated. Collected data analysed by 
statistical methods in SPSS.
19  
RESULTS 
Of all patients, 46% were female with mean age 72±12.3 
(40-89). 41% of all patients have HTN which the upper 
risk factor is in this group. Among patients, the most type 
of ischemia was cortical in MCA area (32%) (Figure 1). 
From all patients with cortical stroke, 20 (43.5%) were in 
case and other in control group. All patients followed in 
24,48,144 hour after beginning symptoms and also in 
three months based on NIHSS score and results showed 
that after 1-3 days before intervention, there wasn’t 
significant relation between albumin and NIHSS 
decreasing rate but in the first, second and third month 
after intervention the difference was statistically 
significant (Table 1). 
Also results in other patients with stroke in brain stem and 
lacunar showed that there wasn’t any significant relation 
between albumin and NIHSS decreasing score. Of all 
ischemia, ischemia in brain stem have upper and lacunar 
have lower mortality rate (Figure 2).  
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Figure 1: Type of ischemia in all patients. 
 
Figure 2: Mortality rate by ischemia type in all 
patients. 
Table 1: Compare the mean score of NIHSS in 
patients with cortical ischemia. 
Time Group Mean±SD p-value 
One month 
late 
Albumin 28.2±0.5 
0.029 
Normal saline 30.9±5.6 
Two 
month late 
Albumin 26.1±4.94 
0.025 
Normal saline 30.9±3.92 
Three 
month late 
Albumin 24.8±5.1 
0.012 
Normal saline 31.3±3 
DISCUSSION 
Previous studies about relation albumin with clinical signs 
showed that clinical rate of serum albumin in acute 
ischemic stroke decrease the bad prognosis of disease. 
In this study the result obtained that the effect of Albumin 
compare to the normal saline in stroke type cortical is 
effective. Didze and et al in a study by measurement the 
Albumin serum showed that hypoalbuminemia associated 
with mortality and morbidity increasing in patients.
10
 
Famkin and et al in a study showed that 
Hypoalbuminemia is an independent risk factor predictor 
of mortality from ischemic stroke.
11
 
This study showed that there wasn’t any significant 
relation between mortality from stoke and using albumin. 
Babu MS and et al in a study showed that higher rate of 
serum albumin in ischemia stroke decrease from bad 
prognosis of disease.
12
 
According to the Chkaraborty and et al study rate of 
albumin has significant relation with increasing severity 
of disease and long bad prognosis of diseases.
13
 
Yuko and et al showed that higher doses of albumin 
therapy may have neuroprotective effects on ischemic 
stroke.
14
 
Various study showed that Neuroprotective effects of 
Albumin significantly decrease if more than 4-5 hours 
after beginning stroke symptoms is past.
15,16
 Experimental 
studies showed that albumin therapy in moderate to high 
doses (0.63-2.5 g/kg) in distance 2-4 hour after beginning 
stroke signs has major impact on reduce the size of 
infarction, cerebral edema and improvement of 
neurological symptoms.
17
 
This study showed that albumin is effective on cortical 
stoke because serum albumin has multilevel micro-
vascular effects and not only reduces the haematocrit, but 
also reduces the accumulation of erythrocytes and 
albumin is also an important antioxidant action against the 
oxidizing agents.
9,18,19
 
Dziedzic T and et al in a study showed that higher level of 
albumin in stroke patients decrease risk of poor 
outcome.
20
 
CONCLUSION  
Results showed that in ischemic stroke type cortical, there 
was a significant relationship between receiving albumin 
and decreasing NISHH score. But this relation wasn’t 
significant other types of stroke such as Lacunar and brain 
stem. We can result that albumin has an impact on clinical 
practice and complications of ischemic stroke type 
cortical in patients with ischemic stroke. 
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